Rockville, MD, June 28, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer as well as autoimmune disorders and infectious diseases,

Bispecific molecule based on DART® platform simultaneously targets B-cell antigens, CD32B and CD79B MGD010 was well tolerated at all dose levels with no serious adverse effects ROCKVILLE, Maryland, June 10, 2016 (GLOBE NEWSWIRE) --   -- MacroGenics, Inc.

MacroGenics licenses MGD015 to Janssen $75 Million upfront license fee paid to MacroGenics MacroGenics may elect to fund a portion of late-stage development costs in exchange for a U.S. and Canada profit share MacroGenics may elect to co-promote in the United States Rockville, Maryland, May 18,

ROCKVILLE, Maryland, May 11, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

ROCKVILLE, Md., May 10, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that its collaboration partner, Pfizer Inc. (NYSE: PFE), has advanced a bispecific antibody therapeutic candidate generated by MacroGenics' Dual-Affinity Re-Targeting, or DART®, platform.

Eight molecules in clinical development, including six in immuno-oncology On track for three new IND submissions in 2016-2017 Promising pipeline of preclinical candidates shown at recent AACR meeting ROCKVILLE, Md., May 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc.

Rockville, MD, May 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,

ROCKVILLE, Md., April 27, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, May 4, 2016, the Company will release its financial results for the quarter ended March 31, 2016. The Company's management team will host a conference call discussing the Company's

ROCKVILLE, Maryland, April 19, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

Rockville, MD, April 06, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

ROCKVILLE, Maryland, March 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

MGD009 is a bispecific DART molecule that targets B7-H3 and CD3 Redirected T-cell killing of multiple B7-H3-expressing tumor cell lines observed in vitro Dose-dependent inhibition of tumor growth and regression observed in vivo Linear PK and prolonged half-life support dosing at biweekly intervals

Eight molecules in clinical development, including six in immuno-oncology  Multi-national Phase 1b/2 gastric cancer study initiated evaluating the combination of margetuximab and pembrolizumab  Strong balance sheet supports continued advancement of pipeline

ROCKVILLE, Md., Feb. 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

Rockville, Md., Feb. 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

ROCKVILLE, Md. , Dec. 02, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

Anti-B7-H3 antibody is well-tolerated Single-agent, anti-tumor activity observed across several tumor types Initial evidence of T-cell immunomodulatory role ROCKVILLE, Md. , Nov. 07, 2015 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on

Second paper published demonstrating DART molecule potential against HIV Data support HIV research contract recently awarded to MacroGenics by NIAID ROCKVILLE, Md. , Nov. 05, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering

Bi-specific antibody leadership — fifth DART® molecule (MGD009) enters clinical testing B7-H3 franchise advances — Encouraging initial clinical results from ongoing enoblituzumab (MGA271) Phase 1 trial and regional rights regained  Recent collaboration with Merck on immuno-oncology study evaluating

ROCKVILLE, Md. , Nov. 04, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

Rockville, MD , Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 4, 2015 , the Company will release its financial results for the quarter ended September 30, 2015 . The Company's management team will host a conference call discussing the

Servier does not exercise option to license rights for enoblituzumab in its specified territories MacroGenics advances enoblituzumab and pursues integrated B7-H3 franchise strategy Rockville, MD , Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage

Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer

Encouraging initial clinical results from ongoing enoblituzumab (MGA271) trial B7-H3 franchise extended — fifth DART® molecule (MGD009) in Phase 1 Proprietary immune checkpoint PD-1 x LAG-3 DART molecule (MGD013) introduced HIV DART and Trident™ tri-specific platform introduced ROCKVILLE, Md.

--Company to provide in-depth review of its antibody-based technology platforms and broad portfolio of therapeutics being developed to treat cancer, autoimmune disorders and infectious diseases